Merck & Company, Inc. which can be found using ticker (MRK) now have 24 analysts in total covering the stock. The consensus rating is pointing to ‘Buy’. The target price High/Low ranges between 135 and 96 and has a mean target at $118.71. Given that the stocks previous close was at $104.92 this is indicating there is a potential upside of 13.1%. It’s also worth noting that there is a 50 day moving average of $107.21 and the 200 day moving average is $99.06. The market cap for the company is $268,887m. Company Website: https://www.merck.com
The potential market cap would be $304,228m based on the market consensus.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
The company has a dividend yield of 2.76% with the ex dividend date set at 14-3-2023 (DMY).
Other points of data to note are a P/E ratio of 18.55, revenue per share of 23.41 and a 11.96% return on assets.
